Abbvie Inc Stock Performance
| ABBV Stock | USD 159.62 7.67 4.58% |
AbbVie has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AbbVie's returns are expected to increase less than the market. However, during the bear market, the loss of holding AbbVie is expected to be smaller as well. AbbVie Inc right now shows a risk of 1.14%. Please confirm AbbVie Inc coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if AbbVie Inc will be following its price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in AbbVie Inc are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable fundamental drivers, AbbVie is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return (4.58) | Five Day Return (3.27) | Year To Date Return (0.13) | Ten Year Return 213.78 | All Time Return 356.06 |
Forward Dividend Yield 0.0369 | Payout Ratio 0.5455 | Forward Dividend Rate 6.2 | Dividend Date 2024-05-15 | Ex Dividend Date 2024-04-12 |
| AbbVie dividend paid on 15th of February 2024 | 02/15/2024 |
1 | Aldeyra stock gains on plans for AbbVie-partnered drug | 03/28/2024 |
2 | Dry Eye Syndrome Market Set for Rapid Growth as Aging Population Demand Soars - Global Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com | 04/05/2024 |
3 | Glancy Prongay Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. on Behalf of Investors | 04/12/2024 |
4 | Johnson Johnson Q1 Earnings Top Estimates | 04/16/2024 |
5 | AbbVie Increases Despite Market Slip Heres What You Need to Know | 04/17/2024 |
6 | Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis | 04/18/2024 |
7 | The Global Market for HPV Associated Disorders, 2018-2023 and 2024-2033, Featuring Profiles of Leading Players AstraZeneca, Roche, Biocon, GlaxoSmithKline, and ... | 04/19/2024 |
8 | Loratadine Market to Garner 221.4 Billion, Globally, by 2033 at 3.1 percent CAGR The Brainy Insights | 04/22/2024 |
9 | Gear Up for AbbVie Q1 Earnings Wall Street Estimates for Key Metrics | 04/23/2024 |
10 | Can a new batch of tech earnings rescue the market Here are the factors at play | 04/25/2024 |
| Begin Period Cash Flow | 9.2 B | |
| Total Cashflows From Investing Activities | -2 B |
AbbVie |
AbbVie Relative Risk vs. Return Landscape
If you would invest 16,239 in AbbVie Inc on January 27, 2024 and sell it today you would earn a total of 490.00 from holding AbbVie Inc or generate 3.02% return on investment over 90 days. AbbVie Inc is currently generating 0.0537% in daily expected returns and assumes 1.139% risk (volatility on return distribution) over the 90 days horizon. In different words, 10% of stocks are less volatile than AbbVie, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AbbVie Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AbbVie's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AbbVie Inc, and traders can use it to determine the average amount a AbbVie's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0471
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | ABBV | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.14 actual daily | 10 90% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average AbbVie is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AbbVie by adding it to a well-diversified portfolio.
AbbVie Fundamentals Growth
AbbVie Stock prices reflect investors' perceptions of the future prospects and financial health of AbbVie, and AbbVie fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AbbVie Stock performance.
| Return On Equity | 0.35 | ||||
| Return On Asset | 0.0807 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 344.21 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Price To Earning | 21.28 X | ||||
| Price To Book | 27.74 X | ||||
| Price To Sales | 5.29 X | ||||
| Revenue | 54.32 B | ||||
| Gross Profit | 41.53 B | ||||
| EBITDA | 18.1 B | ||||
| Net Income | 4.88 B | ||||
| Cash And Equivalents | 11.88 B | ||||
| Cash Per Share | 6.72 X | ||||
| Total Debt | 59.38 B | ||||
| Debt To Equity | 4.37 % | ||||
| Current Ratio | 0.93 X | ||||
| Book Value Per Share | 5.87 X | ||||
| Cash Flow From Operations | 22.84 B | ||||
| Earnings Per Share | 2.72 X | ||||
| Market Capitalization | 297.12 B | ||||
| Total Asset | 134.71 B | ||||
| Retained Earnings | (1000 M) | ||||
| Working Capital | (4.84 B) | ||||
| Current Asset | 16.31 B | ||||
| Current Liabilities | 10.89 B | ||||
About AbbVie Performance
To evaluate AbbVie Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when AbbVie generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare AbbVie Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand AbbVie Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents AbbVie's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 170.40 | 178.92 | |
| Return On Tangible Assets | 0.10 | 0.1 | |
| Return On Capital Employed | 0.18 | 0.21 | |
| Return On Assets | 0.04 | 0.03 | |
| Return On Equity | 0.47 | 0.65 |
Things to note about AbbVie Inc performance evaluation
Checking the ongoing alerts about AbbVie for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AbbVie Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist AbbVie until it has trouble settling it off, either with new capital or with free cash flow. So, AbbVie's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AbbVie Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AbbVie to invest in growth at high rates of return. When we think about AbbVie's use of debt, we should always consider it together with cash and equity. | |
| About 72.0% of AbbVie shares are held by institutions such as insurance companies | |
| Latest headline from cnbc.com: Can a new batch of tech earnings rescue the market Here are the factors at play |
- Analyzing AbbVie's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AbbVie's stock is overvalued or undervalued compared to its peers.
- Examining AbbVie's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AbbVie's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AbbVie's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AbbVie's stock. These opinions can provide insight into AbbVie's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.72 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.